[go: up one dir, main page]

EP1416050A1 - Methode permettant de modifier un enzyme et - Google Patents

Methode permettant de modifier un enzyme et Download PDF

Info

Publication number
EP1416050A1
EP1416050A1 EP02738904A EP02738904A EP1416050A1 EP 1416050 A1 EP1416050 A1 EP 1416050A1 EP 02738904 A EP02738904 A EP 02738904A EP 02738904 A EP02738904 A EP 02738904A EP 1416050 A1 EP1416050 A1 EP 1416050A1
Authority
EP
European Patent Office
Prior art keywords
enzyme
coenzyme
amino acid
mutant
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02738904A
Other languages
German (de)
English (en)
Other versions
EP1416050A4 (fr
Inventor
Takahisa Nakai
Souichi Morikawa
Noriyuki Kizaki
Yoshihiko Yasohara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of EP1416050A1 publication Critical patent/EP1416050A1/fr
Publication of EP1416050A4 publication Critical patent/EP1416050A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Definitions

  • This invention relates to a method for modifying the coenzyme dependency of an oxidoreductase, particularly a method for modifying the coenzyme dependency of an enzyme having an activity of asymmetrically reducing a carbonyl compound to produce an optically active alcohol (hereinafter referred to as CRD enzyme), wherein the enzyme dependency involves the conversion of reduced type ⁇ -nicotinamide adenine dinucleotide phosphate (hereinafter abbreviated to NADPH) to reduced type ⁇ -nicotinamide adenine dinucleotide (hereinafter abbreviated to NADH).
  • NADPH reduced type ⁇ -nicotinamide adenine dinucleotide phosphate
  • NADH reduced type ⁇ -nicotinamide adenine dinucleotide
  • This invention further relates to a process for producing a CRD enzyme mutant having NADH dependency obtained by said modification method, a DNA encoding said enzyme mutant, a plasmid carrying this DNA, a transformed cell obtained by transformation with this plasmid, and said enzyme.
  • This invention also relates to a process for producing an optically active alcohol using the aforementioned enzyme and this transformed cell.
  • An optically active (S)-4-halo-3-hydroxybutyric ester is a compound to be utilized for an intermediate for production of a medicine or the like.
  • the method of production of a symmetric, optically pure version thereof is an important subject with industrial applications. Therefore, process development is enthusiastically explored in order to produce an optically active alcohol such as (S)-4-halo-3-hydroxybutyric ester or the like using a CRD enzyme, which asymmetrically reduces a carbonyl compound such as 4-haloacetoacetic ester or the like.
  • CMCRD enzyme a CRD enzyme derived from Candida magnoliae reported by a part of the present inventors, a process for producing a practical (S)-4-halo-3-hydroxybutyric ester was first provided (WO 98/35025).
  • This CMCRD enzyme has excellent thermostability and organic solvent resistance and has satisfactorily high enzyme activity.
  • NADP ⁇ -nitotinamide adenine dinucleotide phosphate
  • NAD ⁇ -nitotinamide adenine dinucleotide
  • GDH glucose dehydrogenase
  • FDH formic acid dehydrogenase
  • alcohol dehydrogenase amino acid dehydrogenase
  • organic acid dehydrogenase such as malate dehydrogenase
  • GDH includes types which can regenerate NADP and types which can regenerate NAD, but FDH can regenerate NAD alone.
  • This invention purposes to provide a rational enzyme modification method for converting the coenzyme dependency of an oxidoreductase in order to solve the problems described above.
  • This invention further purposes to provide a CRD enzyme mutant which can utilize NADH as a coenzyme according to said modification method, a DNA encoding said CRD enzyme mutant and a recombinant into which the DNA is introduced, and a process for producing an optically active (S)-4-halo-3-hydroxybutyric ester using the same.
  • the present inventors developed an enzyme modification method converting the coenzyme-dependency of an oxidoreductase, succeeded in preparation of a CRD enzyme mutant which can utilize NADH as a coenzyme according to said enzyme modification method, and completed the present invention.
  • the present invention relates to a method for modifying an enzyme in order to convert the coenzyme-dependency of an oxidoreductase, characterized in that the size of binding energy of a coenzyme molecule is controlled by the substitution, insertion, deletion or the combination thereof of a single or plural arbitrary amino acid residue at the previously selected site of said oxidoreductase.
  • the above enzyme modification method includes a step of identifying an active site of an oxidoreductase, a step of determining an amino acid residue interacting with a coenzyme molecule in the neighborhood of said active site, and a step of carrying out mutation treatment in order to control the size of the binding energy of the coenzyme molecule over said determined residue.
  • the aforementioned step of specifying the active site in the above enzyme modification method further includes treatments of predicting the three dimensional structure by molecule modeling method, searching for the cleft part having a volume capable of accommodating a coenzyme molecule, comparing amino acid sequences of the enzyme with an analogous enzyme protein, and extracting residues presumed to be important for the binding of enzyme and coenzyme molecules from the amino acid residues constituting said cleft part.
  • the oxidoreductase in the above enzyme modification method is the one utilizing pyridine nucleotide coenzyme as a coenzyme molecule.
  • the oxidoreductase in the above enzyme modification method is a carbonyl oxidoreductase, particularly preferably the one derived from Candida magnoliae IFO 0705.
  • the present invention relates to a carbonyl oxidoreductase mutant, which is obtained from a wild-type carbonyl oxidoreductase by substitution, insertion, deletion or the combination thereof of an amino acid residue and which has the following physicochemical properties:
  • the present invention relates to an oxidoreductase mutant obtained by the above enzyme modification method, a DNA encoding said enzyme mutant, a plasmid carrying said DNA, and a transformant obtained by transformation with said plasmid.
  • the present invention relates to a process for producing of a carbonyl reductase mutant, said process comprising a step of culturing and proliferating the above transformant.
  • the present invention relates to a process for producing an optically active alcohol, said process including a step of reacting the above enzyme mutant, an enzyme having an ability of regenerating a coenzyme which said enzyme mutant depends upon and/or a mutant thereof and a carbonyl compound, and a step of harvesting the produced optically active alcohol.
  • oxygenoreductase means an enzyme catalyzing oxidation-reduction reaction and utilizing, for example, a pyridine dinucleotide coenzyme such as NADP, NAD and the like, quinines such as ubiquinone and the like, a disulfide compound such as glutathione and the like, cytochromes, pteridine compounds, oxygen, hydrogen peroxide, etc. as electron (hydrogen) donors.
  • carbonyl reductase means an enzyme (CRD enzyme) having activity of asymmetrically reducing a carbonyl compound to produce an optically active alcohol.
  • amino acids, peptides and proteins are expressed using the abbreviations set forth below which are adopted by the IUPAC-IUB Committee of Biochemical Nomenclature (CBN).
  • amino acid sequences of a peptide and a protein will be expressed so that the N-terminal is located on the left end while C-terminal is located on the right end, and so that the first amino acid is located on the N-terminal.
  • the linkage of amino acid residues is expressed by "-". For example, it may be expressed as Ala-Gly-Leu. In case that the same amino acid residues continues, it may be expressed, for example, as (Ala) 3 , which is the same as Ala-Ala-Ala.
  • a mutant of an enzyme is a modified enzyme having an amino acid sequence obtained by substituting, inserting, deleting or modifying at least one or more amino acids of the amino acid sequence of the original enzyme and having at least some of the activities of the original enzyme.
  • amino acid mutation to be utilized for the designing of a mutant insertion, deletion or modification of an amino acid can be enumerated in addition to substitution.
  • the substitution of an amino acid means the substitution of 1 or more, for example 1 to 20, and preferably 1 to 10, amino acids for the original peptide.
  • the addition of an amino acid means the addition of 1 or more, for example, 1 to 20, and preferably 1 to 10, amino acids to the original peptide chain.
  • the deletion of an amino acid means the deletion of 1 or more, for example, 1 to 20, and preferably 1 to 10, amino acids from the original peptide.
  • design method or “molecular design technique” of a mutant molecule means analyzing the amino acid sequence and the three dimensional structure of a protein or a polypeptide molecule (e.g., a natural molecule) before mutation to predict what kind of properties (e.g., catalytic activity, interaction with other molecules, etc.) individual amino acids have and to calculate an amino acid mutation suitable for producing the desired property modification (e.g., improvement of catalytic activity, improvement of protein stability, etc.).
  • This designing method is preferably carried out using a computer.
  • Swiss-PDB Viewer [Swiss Institute of Bioinformatics (SIB), ExPASy Molecular Biology Server (available from http://www.expasy.ch/ )] as a program for mutation introduction modeling, AMBER (D. A. Pearlman et al., AMBER 4.1, University of California, San Francisco, 1995) and PRESTO [Morikami K. et al., Comput. Chem. , 16, 243-248 (1992)] as programs for three dimensional structure optimization including energy minimization of a protein and computation of molecular dynamics, and Shrike (JP Patent Application No. 11-368498 (1999) : JP Patent Publication No. 2001-184381 A) as programs for computing the optimum amino acid mutation, etc. can be enumerated.
  • the enzyme modification method for converting the coenzyme-dependency of an oxidoreductase according to the present invention will be described below in detail, taking a CMCRD enzyme as an example.
  • the present invention is in no way restricted particularly to the CMCRD enzyme to be described below, and it is obvious to a person skilled in the art that the same method can be applied to various oxidoreductases including the CRD enzyme.
  • the three dimensional structure of the CMCRD enzyme is unknown because experiments thereon such as structural analysis and the like, including X-ray crystal structure analysis, have not been carried out.
  • the present enzyme modification method more efficient molecular design of an enzyme mutant was achieved by utilizing the three dimensional structure of an enzyme. Therefore, it is, first of all, required to obtain the three dimensional structure of a complex in which a wild-type CMCRD enzyme and a coenzyme molecule are bound, so that the prediction of the three dimensional structure of the CMCRD enzyme according to the molecular modeling and the modeling are carried out in the present invention.
  • the three dimensional structure of a complex with a CMCRD enzyme and a coenzyme can be constructed according to the following procedures.
  • Step 1 On the basis of the amino acid sequence of a CMCRD enzyme, multiple amino acid sequence alignments with enzymes which have amino acid sequence homology and whose three dimensional structures are registered in Protein Data Bank (PDB) are prepared utilizing a ClustalX program [Thompson, J. D. et al., Nucleic Acids Res. 22, 4673-4680 (1994)].
  • a protein having amino acid homology with the CMCRD enzyme to be utilized for molecular modeling can be selected by screening the amino acid sequences of the proteins registered in PDB for amino acid sequence homology by using a PASTA [Perason W. R.
  • a protein having a homology score (the E value on the BLAST program) of at least 1 ⁇ 10 -5 or less, preferably of 1 ⁇ 10 -10 or less with the amino acid sequence of CMCRD enzyme may be used for multiple amino acid sequence alignment as a protein having known three dimensional structure.
  • proteins having the PDB IDs 1AE1, 2AE2, 1FMC, 1CYD, 1HDC, 1YBV, 1BDB and 1EDO can be used.
  • Step 2 these proteins having known three dimensional structures are subjected to three-dimensional alignment by using the MAPS program [G. Lu, J. Appl. Cryst. (2000), 33:176-183] to modify multiple alignments previously obtained from the amino acid sequences alone on the basis of three dimensional structure analogy, whereby final multiple sequence alignments to be used for the molecular modeling can be obtained. It is desired that the modification of the sequence alignment is carried out on the basis of three dimensional structure analogy in such way that insertion or deletion does not occur in the secondary structure of ⁇ -helix, ⁇ -sheet or the like.
  • a protein presumed to have high three dimensional structure analogy with insertion or deletion sites as few as possible can be selected as a template protein of molecular modeling.
  • the three dimensional structures of enzymes having PDB IDs of 1AE1, 2AE2, 1FMC, 1CYD, 1HDC, 1YBV, 1BDB 1EDO and the like, and preferably those of 1YBV, 1EDO and 1FMC can be utilized as templates.
  • These template proteins are displayed on the three-dimensional Swiss-PDB Viewer graphics program, and, on the basis of the sequence alignment obtained in Step 2, the substitution of the amino acid residues can be carried out over the amino acid sequence of the CMCRD enzyme.
  • Step 4 With respect to the insertion site and the deletion site, PDB is screened for the most suitable three dimensional structure of an analogous part and the three dimensional structure of said part is substituted, whereby a three dimensional structure model can be constructed.
  • the molecular modeling of the insertion site or the deletion site can be carried out by screening of high resolution three dimensional structure registered in PDB, preferably protein three dimensional structure having a resolving power of 2.0 ⁇ or less for a partial three dimensional structure. This is most suitable for the partial three dimensional structure of the main chain of the template protein including the periphery of the insertion site or the deletion site.
  • a partial protein three dimensional structure having a root mean standard deviation (RMSD) of 2.0 ⁇ or less can be used when carrying out least-square superposition of the atomic coordinate of the partial three dimensional structure of the main chain of a template protein.
  • RMSD root mean standard deviation
  • Step 5 With respect to the three dimensional structure of a coenzyme NADP, which can be bound to the CMCRD enzyme, a space having a volume enabling the accommodation of NADP molecules on the three dimensional structure of the CMCRD enzyme, that is, the cleft part, is identified. Then interaction between amino acid residue group existing on the cleft part an NADP molecules is identified, whereby the atomic coordinate of the NADP can be determined.
  • a method for determining the atomic coordinate of NADP a method comprising selecting proteins binding NADP, PDB ID, 1AE1, 2AE2, 1CYD, 1YBV, and 1EDO, preferably 1YBV from the three dimensional structurally analogous proteins, and substituting the atomic coordinate of this NADP of the 1YBV can be exemplified.
  • the atomic coordinate can be determined by firstly constructing a 3-D structural model of a CMCRD enzyme alone to which a coenzyme is not bound, then, simultaneously identifying a space having a volume enabling the accommodation of NADP molecules, that is, the cleft part with the guidance of 3-D structural energy and the interaction between amino acid residue group existing in the cleft part and the NADP molecules by using programs of molecular docking such as Autodock [(Oxford Molecular), Guex, N. and Peitsch, M. C. (1997)] after whereby the atomic coordinate of the NADP molecule can be determined.
  • the three dimensional structure model of a CMCRD enzyme-NADP complex can be constructed.
  • the finally constructed three dimensional structure model can be optimized in three dimensional structure by energy minimization calculation and molecular dynamics calculation.
  • AMBER, PRESTO and the like can be used.
  • a three dimensional structure model containing amino acid sequence having 30% or more homology, preferably 50% or more homology, and further preferably 70% or more homology, with that of the CMCRD enzyme which is subjected to an enzyme modification method of a CMCRD enzyme can be constructed.
  • the identification of the active sites (catalytic site and binding site), and that of amino acid residues interacting with coenzyme molecules in the neighborhood of said active sites can be carried out according to the following method.
  • the amino acid sequence in common between the CMCRD enzyme and the analogous CRD enzyme can be (Gly or Ala)-(Xaa) 3 -(Gly, Ala or Thr)-(Ile or Leu)-(Gly, Ala or Ser)-(Xaa) 10 -(Gly or Asn).
  • a region neighboring the region containing this common amino acid sequence on the three dimensional structure of a complex in other words, a region important for the binding between an enzyme and a coenzyme, can be identified.
  • the coenzyme-dependency can be modified.
  • amino acid residue positions of the CMCRD enzyme at Positions 40 to 69, 87 to 92 and 225 to 228, and preferably Positions 40 to 69 can be enumerated. Further preferably, amino acid residue positions 41 to 43, 47, 63 to 66 and 69 can be enumerated as sites to be selected.
  • the distance as an indication, it is possible to select an amino acid residue interacting with a coenzyme molecule. For example, by making a distance within 12 ⁇ , and preferably within 8 ⁇ , from the coenzyme binding site as an indication, it is possible to select a site into which mutation is introduced.
  • amino acid residues making great contribution to the binding of a NADP or NADPH coenzymes are identified by the evaluation of nonbinding interaction with coenzyme molecules by the calculation of 3-D structural energy, the calculation of electrostatic potential with attention to electrostatic interaction, and other methods.
  • the contribution of every amino acid residue in the selection region to the binding of the NADP or NADPH coenzymes can be estimated by the calculation of electrostatic potential set forth below.
  • the point charge was given to atoms of all the amino acid residues, followed by calculation of the electrostatic contribution to the charge of -1 placed on phosphoric acid residues of all the residues other than 2'-phosphoric acid residue of NADP.
  • the size of binding stabilization of every amino acid residue to NADP can be obtained.
  • Ser 42, Tyr 64, Asn 65 and Ser 66 form positive electrostatic fields to the 2'-phosphoric acid residue of NADP, thereby contributing to the stabilization of binding to NADP.
  • Candidates for amino acid substitution can be obtained by screening the three dimensional structure models of the CMCRD enzyme-NADP complex and the CMCRD enzyme-NAD complex for the above residue sites by computer screening using, for example, ashrike program (JP Patent Application No. 11-368498 (1999): JP Patent Application (Kokai) No. 2001-184381).
  • the candidates for amino acid mutant can be calculated taking into account the difference between the binding energy to NADP and that to NAD and the denatured free energy as an indication of the enzyme thermostability accompanied by the amino acid substitution. Furthermore, the multiple amino acid sequence alignments at the coenzyme binding site of CRD enzyme having known three dimensional structure can be utilized as a reference for amino acid substitution.
  • the coenzyme dependency of an enzyme to be subjected to the regeneration of a coenzyme to be combined with the CRD enzyme also can be modified. Furthermore, it is obvious that the conversion of the substrate-specificity of the CRD enzyme becomes possible by applying the same designing technique if a molecule to be considered is changed from a coenzyme to a substrate.
  • S41A, S42A, S42R, S43Q, S43G, S43R, W63I, W63L, W63V, W63F, W63M, Y64D, N65I, N65V, S66N, S66L, Y47R and A69E are enumerated as mutation candidates, and further preferably, it is possible to design mutants resulting from combinations of the above single mutations as CRD enzyme mutants.
  • CMCRD enzyme mutants in the present invention the following mutants were obtained from natural CMCRD enzymes by substitution, insertion, deletion or their combination of amino acid residues:
  • the present CRD enzyme mutants obtained according to the above methods have the physicochemical properties described in the following (1) to (3):
  • the introduction of mutation into a gene can be carried out by utilizing one of the known in vitro mutation techniques, such as a site-specific mutation method or the like, although there is no restriction thereto.
  • the introduction of mutation can be carried out as follows. All amino acid mutations which should be introduced exist in the approx. 170-bp restriction enzyme Eco O109I- Eco O109I site of the wild-type CMCRD enzyme gene.
  • the mutations can be introduced by synthesizing DNA fragments into which mutations have been introduced, corresponding to this site, followed by substituting said DNA fragments for the Eco O109I - Eco O109I site of a recombinant plasmid pNTS1 (W098/35025) containing the wild-type CMCRD enzyme gene.
  • DNA having nucleotide sequences SEQ ID NO:1 to 9 are synthesized and subcloned in the Pst I site of pUC18 to produce plasmids pUCSYN181 to pUCSYN189.
  • Escherichia coli JM109 or HB101 can be transformed by plasmids pUCSYN181 to pUCSYN189..
  • the aimed DNA fragments can be isolated by recovering plasmids from the obtained transformant, digesting the plasmids with Eco O109I and then subjecting the resultant to preparative polyacrylamide electrophoresis.
  • digesting the plasmid pNTS1 with Eco O109I approx. 3.2-kb DNA fragments can be recovered by subjecting the digest to preparative agarose gel electrophoresis.
  • recombinant plasmids pNTS1M1, pNTS1M2, pNTS1M3, pNTS1M4, pNTS1M5, pNTS1M6, pNTS1M7, pNTS1M8 and pNTS1M9 in which mutant genes are inserted into the Eco O109I - Eco O019I site of the pNTS1 can be constructed.
  • the amino acid mutation to be introduced can be carried out by preparing DNA fragments containing mutation sites according to PCR and then confirming the base sequences thereof to recombinant plasmids.
  • a primer carrying a base sequence upstream the Nde I site can be preferably used for the preparation of DNA fragments for the base sequence analysis.
  • the obtained recombinant plasmid carrying a CRD enzyme gene can be introduced into a particular host cell according to an ordinary method.
  • a host cell There is no restriction to a host cell, and a microorganism, yeast, a filamentous fungus, a plant cell, an animal cell or the like may be used, with the use of Escherichia coli being particularly preferable.
  • methods known to a person skilled in the art for example, a method including a step of mixing a host cell in the competent state and a recombinant plasmid, a method including a step of introduction by conjugative transport using a helper plasmid, and others can be enumerated.
  • a transformant producing the CRD enzyme mutant can be obtained by transforming Escherichia coli JM109 or HB101 with the above plasmid.
  • the reduction activity to 4-chroloacetoacetic ester can be confirmed as follows.
  • Method for determining reduction activity to 4-chloroacetic ester After carrying out a reaction in a reaction solution containing 0.1M potassium phosphate buffer (pH 6.5), 0.167mM NADH or NADPH, 1mM ethyl 4-chloroacetate and an enzyme at 30°C, the decrease in absorbance at 340 nm accompanied by the decrease of NADH or NADPH is determined.
  • One U represents an amount of enzyme catalyzing a decrease of 1 ⁇ mol of NADH or NADPH for 1 minute. In case that NADH or NADPH cannot be used as a coenzyme, only a small decrease in absorbance at 340 nm is observed under this condition.
  • the assay of a protein is carried out in accordance with the dye-binding method using a protein assay kit manufactured by Bio-Rad Laboratories, Inc.
  • the above CRD enzyme mutant shows a high reduction activity to 4-chloroacetoacetic ester but substantially no dehydrogenase activity (i.e., oxidation activity) to any optical isomers of 4-halo-3-hydroxybutyric ester.
  • substantially no dehydrogenase activity means that the CRD enzyme mutant, when it comes into contact with 4-halo-3-hydroxy-butyric ester acting as a substrate in the presence of NAD, does not show any substantial dehydrogenase activity when the rate of change per unit time in the absorbance at 340 nm accompanied by the increase or decrease of NADH is 5% or less, and preferably 1 % or less, on the relative activity base such that 100% is given to 4-chloroacetic ester.
  • the above CRD enzyme mutant does not substantially show a reductase activity upon acetoacetic ester.
  • the index of the enzyme activity it does not substantially show a dehydrogenase or reductase activity when the rate of change is 5%e or less, and preferably 1% or less, on the relative activity base such that 100% is given to 4-chloroacetic ester.
  • the analyses of the enzyme activity and the coenzyme-dependency of the CRD enzyme mutant can be carried out as follows, for example, using a transformant containing a DNA encoding said enzyme.
  • the transformant is recombinant Escherichia coli HB101 (pNTS1M1)
  • pNTS1M1 Escherichia coli HB101
  • it can be cultured on a medium with proper composition including 50 ⁇ g/ml of ampicillin, preferably on an LB medium and a 2 ⁇ YT medium, and further preferably on a 2 ⁇ YT medium.
  • the harvested microorganism After harvesting the microorganism by centrifugation or the like, the harvested microorganism is suspended in a buffer with a proper pH, for example, 10 to 100mM phosphate buffer (pH 6 to 8) or 10 to 100mM Tris buffer (pH 6 to 8), and preferably 100mM phosphate buffer (pH 6.5), and then disrupted by ultrasonication, whereby a cell-free extract can be prepared.
  • the CMCRD enzyme activity in the cell-free extract is measured according to the above assay method, and the activity of Escherichia coli HB101 (pNTS1) transformed with a plasmid carrying a wild-type CMCRD enzyme gene prepared according to the same method is measured. This is followed by a comparison of these activities.
  • the above CMCRD enzyme mutant reduces 4-chloroacetoacetic ester utilizing NADH as a coenzyme while the enzyme shows absolutely no reduction activity when the NADPH is used as a coenzyme. From this fact, it is confirmed that the targeted conversion (inversion) of coenzyme-dependency was succeeded.
  • extraction and purification methods ordinarily available to a person skilled in the art can be used. For example, after centrifuging microbial cells from a culture medium, the microbial cells are suspended in an appropriate buffer and then disrupted or dissolved applying physical techniques such as use of glass beads, ultrasonication, etc., or biochemical techniques such as use of enzymes, etc. Then solid matters in said culture solution are removed by centrifugation, whereby a crude solution of the enzyme can be obtained.
  • the above crude enzyme solution can be further purified by techniques ordinarily available to a person skilled in the art, for example, by using ammonium sulfate precipitation, dialysis, or chromatography singly or in combination.
  • chromatography various chromatography such as hydrophobic chromatography (e.g., phenyl Sepharose), ion exchange chromatography (e.g., DEAE Sepharose), gel filtration, etc. can be used singly or in combination, whereby a CRD enzyme mutant according to the present invention can be obtained.
  • hydrophobic chromatography e.g., phenyl Sepharose
  • ion exchange chromatography e.g., DEAE Sepharose
  • gel filtration etc.
  • optically active alcohols can be produced from their corresponding ketone compounds by utilizing the aforementioned CRD enzyme mutant.
  • the CRD enzyme mutant according to the present invention is advantageous in industrial application because it can utilize NADH, which is cheaper and more stable than NADPH, as a coenzyme.
  • the target enzymatic reaction can be carried out by making the enzyme molecule, a treated matter thereof, a culture containing the enzyme molecule or a transformant of a microorganism or the like producing the enzyme come into contact with a reaction solution in a viable state.
  • the form of the contact between the enzyme and a reaction solution is in no way restricted to these examples.
  • the reaction solution is such that a substrate and NADH as a coenzyme necessary for enzymatic reaction are dissolved in an appropriate solvent necessary for providing circumstances desirable for the expression of enzyme activity.
  • a treated matter of a microorganism containing the CRD enzyme mutant according to the present invention includes a microorganism having cell membrane of which permeability is changed by treatment with an organic solvent such as a surfactant, toluene or the like, a cell-free extract obtained by disrupting microbial bodies by glass beads, ultrasonication or enzymatic treatment, a partially purified cell-free extract, etc. are included specifically.
  • 2,3-butanedione and a 4-haloacetoacetic ester derivative, having adjacent diketones are suitable for use.
  • halogens of the 4-haloacetoacetic ester derivative bromine, chlorine and iodine are enumerated, among which chlorine is particularly suitable for use.
  • esters esters of alcohol including alcohol containing straight chain, branched chain or aromatic substitution, such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, octyl ester, benzyl ester, etc.
  • ethyl ester is the most suitable for use.
  • 4-haloacetoacetic acid derivatives derivatives at the 2-position having analkyl group including a straight chain or a branched chain, or halogens such as chlorine, bromine, iodine, etc may be enumerated.
  • An optically active 4-halo-3-hydroxybutyric ester as a kind of optically active alcohol is obtained, for example, as follows.
  • 4-haloacetoacetic ester represented by the following general formula: (wherein R1 is a halogen, R2 is hydrogen, and R3 is a substituted or unsubstituted alkyl group or an aryl group) can be used.
  • R3 is an alkyl group
  • the R3, for example is a methyl group, an ethyl group, a propyl group, a butyl group or an isopropyl group.
  • R3 is an aryl group, it is, for example, a phenyl group or a tolyl group.
  • the above R3 is a substituted aryl group, it is, for example, a fluorophenyl group, a chlorophenyl group or the like.
  • R1 is chlorine or bromine and R3 is an alkyl group having 1 to 4 carbons.
  • the aforementioned substrate is methyl 4-chloroacetoacetate , ethyl 4-chloroacetoacetate, methyl 4-bromoacetoacetate or ethyl 4-bromoacetoacetate.
  • ethyl 4-iodoacetoacetate, ethyl 4-hydroxyacetoacetate, ethyl 2-chloro-3-oxobutyrate, ethyl 2-methyl-3-oxobutyrate, ethyl 4-azidoacetoacetate or the like can be used as the aforementioned substrate.
  • This 4-haloacetoacetic ester can be prepared according, for example, to the method described in JP Patent Application (Kokai) No. 61-146191 A (1986).
  • 4-haloacetoacetic ester may be prepared according to a method using diketene as a starting material, reacting a halogen thereto to prepare a 4-haloacetoacetic halide and acting an alcohol thereon, a method comprising using an acetoacetic ester as a starting material and directly halogenizing the 4-position of the acetoacetic ester, or the like.
  • the reaction can be carried out by adding a substrate 4-haloacetoacetic ester, a NADH coenzyme and a culture of said transformed microorganism or a treated matter thereof in water, in organic solvent having sparse solubility of water such as ethyl acetate, butyl acetate, toluene, chloroform, n-hexane or the like, or in an appropriate solvent such as a two phase system with an aqueous medium, followed by stirring under adjustment of pH.
  • the reaction is carried out at a temperature of 10 to 70°C at a pH of 4 to 10.
  • the concentration of a substrate to be added is 0.1 % to 90 %(w/v), which, however, can be added continuously.
  • the reaction can be carried out by batch process or continuous process. It is also possible to carry out the reaction according to the present invention by utilizing an immobilized enzyme, a membrane reactor or the like.
  • the treated matters of a microorganism means, for example, a crude extract, cultured microbial bodies, lyophilized microorganisms, acetone-dried microorganisms or the disrupted matters of those microbial bodies. Furthermore, they can be used in a state where an enzyme itself or a microorganism per se is immobilized according to a known means. Immobilization can be carried out according to methods known to a person skilled in the art (e.g., crosslinking method, physical adsorption method, inclusion method or the like).
  • the regeneration of NAD, which is formed from NADH accompanied by these reduction reactions, into NADH can be carried out using microorganisms having ability to reduce NAD (glycolytic pathway, C 1 compound-assimilation pathway of methylotroph, or the like).
  • the reduction of NAD can be reinforced by adding glucose, ethanol, formic acid or the like to the reaction system.
  • the regeneration of NADH can be carried out using partially or fully purified GDH, FDH, alcohol dehydrogenase, amino acid dehydrogenase, or organic acid dehydrogenase (malate dehydrogenase or the like) or the like, microorganisms containing these enzymes and treated matters thereof.
  • a method using GDH and glucose can be enumerated.
  • the reaction conditions differ depending upon the enzyme, microorganism or treated matter thereof to be used, substrate concentration and the like, ranges a substrate concentration of approx. 0.1 % to 90 % wt%, a reaction temperature of 10 to 50°C, a pH of 4 to 8 and a reaction time of 1 to 60 hours.
  • the 4-halo-3-hydroxybutyric ester formed by the reaction can be purified according to an ordinary method.
  • the 4-halo-3-hydroxybu-tyric ester can be purified by removing suspensoids such as microbial bodies or the like by carrying out a treatment such as centrifugation, filtration or the like as the occasion demands, extracting the treated suspension with an organic solvent such as ethyl acetate, toluene or the like, dehydrating the extract with a dehydrating agent such as sodium sulfate or the like, removing the organic solvent under reduced pressure and then subjecting to distillation under reduced pressure, chromatography (e.g., silica gel column chromatography) or the like.
  • chromatography e.g., silica gel column chromatography
  • the 4-halo-3-hydroxybutyric ester can be quantified by gas chromatography.
  • the quantification of ethyl 4-chloro-3-hydroxybutyrate can be carried out by performing chromatography at 150°C using a glass column (ID 3 mm ⁇ 1 m) filled with PEG-20M Chromosorb WAWDMCS (10%, 80/100 mesh; manufactured by G.L. SIENCE, Inc.) and then detecting with FID.
  • the determination of the optical purity of ethyl (S)-4-halo-3-hydroxybutyrate can be carried out by high performance liquid chromatography (HPLC) using a CHIRALCEL OB optical separation column (manufactured by Daicel Chemical Industries, Ltd.).
  • the three dimensional structures of two enzymes 11YBV and 1FMC were selected as the basic three dimensional structures and then subjected to the substitution of amino acid residues on a Swiss-PDB Viewer three-dimensional graphic program [Swiss Institute of Bioinformatics (SIB), ExPASy Molecular Biology Server (available from http://www.expasy.ch/ )].
  • SIB Bioinformatics
  • ExPASy Molecular Biology Server available from http://www.expasy.ch/
  • the atomic coordinate of the coenzyme NADP was constructed by using the atomic coordinate of NADP of 1YBV as a substitute.
  • the finally constructed three dimensional structure models were optimized by calculations of energy minimization and molecular dynamics. Hereinafter, procedures for molecular modeling will be described in detail.
  • candidates for the amino acid substitution were calculated taking into account the difference in binding energy between NADP and NAD and free energy as an indication of (thermo)stability of an enzyme accompanied by the amino acid substitution.
  • multiple amino acid sequence alignments at coenzyme-binding sites of carbonyl reductase having known three dimensional structures given in Table 2 were also utilized as a reference for amino acid substitution.
  • ID means the Protein Data Bank (PDB) registration number
  • PDB Protein Data Bank
  • a DNA having a nucleotide sequence of SEQ ID NO:1 was synthesized, followed by transforming E. coli JM109 (manufactured by Takara Shuzo Co., Ltd.) with 0.2 ⁇ g of a plasmid pUCSYN181 (manufactured by Takara Shuzo Co., Ltd.) prepared by subcloning the synthesized DNA into the Pst I site of pUC18.
  • the plasmid was recovered from the obtained transformant using FlexiPrep (manufactured by Pharmacia, Inc.) and digested with Eco O109I, followed by subjecting the resultant to preparative polyacrylamide gel electrophoresis to isolate a 167-bp DNA fragment.
  • a plasmid pNTS1 (WO098/35025) was digested with Eco O109I, subjected to preparative agarose gel electrophoresis to recover an approx. 3.2-kb DNA fragment, and then the DNA fragments were treated with BAP. Both DNA fragments were ligated using Takara Ligation Kit Ver. 2 (manufactured by Takara Shuzo Co., Ltd.), thereby obtaining a recombinant plasmid pNTS1M1 in which a mutant gene was inserted into the Eco O109I - Eco O109I site of the pNTS1. Using this plasmid, E.
  • E. coli HB101 (manufactured by Takara Shuzo Co., Ltd.) was transformed, thereby obtaining E. coli HB101(pNTS1M1).
  • plasmids in which mutant genes were inserted into the Eco O109I - Eco O109I site of the pNTS1 were prepared, followed by obtaining recombinant E .
  • HB101 (pNTS1M2), HB101 (pNTS1M3), HB101 (pNTS1M4), HB101 (pNTS1M5), HB101 (pNTS1M6), HB101 (pNTS1M7), HB101 (pNTS1M8), and HB101 (pNTS1M9) from respective plasmids.
  • coli HB101 (pNTS1M1), HB101 (pNTS1M2) and HB101 (pNTS1M3) were respectively deposited in International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (1-banchi Chuo the 6 th , Higashi 1-chome, Tsukuba-shi, Ibaraki Prefecture, Japan) on June 22, 2001, with the accession Nos. FERM P-18388, FERM P-18389 and FERM P-18390 out of which FERM P-18388 was converted to the deposit under Budapest Treaty with the accession No. FERM BP-8059 on May 27, 2002.
  • E E .
  • coli HB101(pNTS1M4) and HB101(pNTS1M6) were both deposited in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (1-banchi Chuo the 6 th , Higashi 1-chome, Tsukuba-shi, Ibaraki Prefecture, Japan) on December 4, 2001, with the accession Nos. FERM P-18647 and FERM P-18648, out of which FERM P-18647 was converted to the deposit under the Budapest Treaty on May 27, 2002, with the accession No. FERM BP-8060.
  • the introduced amino acid mutations were confirmed by preparing DNA fragments containing mutation sites by PCR using a primer carrying a base sequence upstream of the Nde I site of the recombinant plasmid and comparing them with the recombinant plasmid in base sequence using an ABI373A DNA Sequencer (manufactured by Applied Biosystems).
  • HB101 (pNTS1M1), HB101 (pNTS1M2), HB101 (pNTS1M3), HB101 (pNTS1M4), HB101 (pNTS1M5), HB101 (pNTS1M6), HB101 (pNTS1M7), HB101 (pNTS1M8) and HB101 (pNTS1M9) obtained in Example 3 were each cultured in 2 ⁇ YT media each containing 50 ⁇ g/ml of ampicillin, harvested, suspended in 0.1M phosphate buffer (pH 6.5) and then ultrasonically disrupted to obtain cell-free extracts.
  • the CMCRD enzyme activities of these cell-free extracts were determined as follows.
  • the enzyme activities were determined by adding 1mM ethyl 4-chloroacetoacetate as a substrate, 0.167mM NADH or NADPH as a coenzyme and the enzyme to 0.1M phosphate buffer (pH 6.5), followed by determining the decrease in the absorbance at 340 nm at 30°C.
  • the enzyme activity oxidizing 1 ⁇ mol of NADPH (NADH) to NADP + (NAD + ) for 1 minute under these reaction conditions was defined as 1 unit.
  • the thus determined CMCRD enzyme activity in the cell-free extract was expressed as a specific activity (the enzyme activity per mg of protein contained in the extract), and the activity of E.
  • HB101 Enzyme Specific Activity (U/mg) Activity relative to NADH (%) Activity relative to NADPH (%) HB101 (pNTS1) 6.4 0 100 HB101 (pNTS1M1) 1.1 100 0 HB101 (pNTS1M2) 0.3 30 0 HB101 (pNTS1M3) 0.2 19 . 0 HB101 (pNTS1M4) 3.0 270 0 HB101 (pNTS1M5) 0.4 33 N.D. HB101 (pNTS1M6) 1.2 105 0 HB101 (pNTS1M7) 0.5 46 N.D. HB101 (pNTS1M8) 0.1 7 N.D. HB101 (pNTS1M9) 0.3 30 N.D.
  • E.coli HB101 (pNTS1M1) was cultured in 2L of 2 ⁇ YT medium (16 g of bacto tryptone, 10 g of bacto yeast extract, 5 g/L of salt) containing 50 ⁇ g/ml of ampicillin, followed by centrifugation to prepare microbial cells.
  • the obtained wet microbial cells were suspended in 10mM potassium phosphate buffer (pH 6.5) containing 100 ⁇ M FOIPAN (FOI, manufactured by Ono Pharmaceutical Co., Ltd.), disrupted by ultrasonication and centrifuged to remove residual microbial bodies, thereby obtaining a cell-free extract.
  • the dialysate was subjected to a DEAE-Sepharose (manufactured by Pharmacia, Inc.) column (3.2 ⁇ 22 cm, 175 ml) previously equilibrated with the same buffer to make an enzyme mutant adsorb, and the column was washed with approx. 600 ml of the same buffer.
  • active fractions were eluted by linear gradients of salt (0 to 0.2M). Then, 250 ml of the active fractions were collected, and ammonium sulfate was added thereto to bring it to 70% saturation and dissolved, and the formed precipitate was collected by centrifugation.
  • E. coli HB101 (pNTS1M1) obtained in Example 3 was inoculated in 100ml of sterilized 2 ⁇ YT medium in a 500-ml Sakaguchi flask (4 flasks), cultured by shaking at 37°C for 44 hours and centrifuged to prepare microbial cells.
  • the obtained wet microbial cells were suspended in 25 ml of 10mM phosphate buffer (pH 6.5) and then ultrasonically disrupted to obtain an enzyme solution.
  • the quantification of ethyl 4-chloro-3-hydroxybutyrate was carried out by gas chromatography. Using a glass column (ID 3 mm ⁇ 1 mm) filled with PEG-20M Chromosorb WAW DMCS 10% 80/100 mesh (manufactured by GL Science, Inc.), chromatography was carried out at 150°C and the detection was carried out by FID. The optical purity of ethyl (S)-4-chloro-3-hydroxybutyrate was measured by HPLC using an optical separation column CHIRALCEL OB (0.46 x 25 cm, manufactured by Daicel Chemical Industries, Ltd.).
  • the chromatography was carried out by using a mixed solvent at a hexane : isopropanol ratio of 9:1 as the mobile phase and setting the flow rate of the mobile phase to 0.8 ml/min.
  • the detection was carried out by monitoring the absorbance at 215 nm.
  • the Escherichia coli HB101 (pNTS1M4) with a high enzyme activity of Example 4 was cultured in 500 ml of 2 ⁇ YT medium (16 g of bacto tryptone, 10 g of bacto yeast extract and 5 g/L of salt) containing 50 ⁇ g/ml of ampicillin and then centrifuged to prepare microbial bodies.
  • a purified preparation of the enzyme mutant was obtained from the obtained wet microbial cells according to the same procedures as in Example 5.
  • the purity of the purified enzyme was analyzed by polyacrylamide gel electrophoresis (SDS-PAGE)., As a result it showed a single band.
  • the enzyme activity was measured under the conditions described in Example 3.
  • a method for modifying oxidoreductase characterized by controlling the binding energy of a coenzyme, an NADH-dependent carbonyl reductase mutant which is advantageous for industrial production and a DNA encoding the same, a plasmid carrying this DNA, a transformant obtained by transformation with this plasmid, and a process for producing an optically active alcohol using this enzyme mutant and/or this transformant are provided.
  • the present enzyme modification method can be meaningfully applied to the conversion of the coenzyme dependency of an enzyme group analogous to the carbonyl reductase according to the present invention.
  • the specification of the present invention includes the specifications and the contents described in the drawings of JP patent applications Nos. 2001-200417 and 2002-006303 as priority applications of the present applications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02738904A 2001-07-02 2002-07-02 Methode permettant de modifier un enzyme et Withdrawn EP1416050A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001200417 2001-07-02
JP2001200417 2001-07-02
JP2002006303 2002-01-15
JP2002006303 2002-01-15
PCT/JP2002/006688 WO2003004653A1 (fr) 2001-07-02 2002-07-02 Methode permettant de modifier un enzyme et

Publications (2)

Publication Number Publication Date
EP1416050A1 true EP1416050A1 (fr) 2004-05-06
EP1416050A4 EP1416050A4 (fr) 2004-12-22

Family

ID=26617964

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02738904A Withdrawn EP1416050A4 (fr) 2001-07-02 2002-07-02 Methode permettant de modifier un enzyme et

Country Status (9)

Country Link
US (1) US20040248250A1 (fr)
EP (1) EP1416050A4 (fr)
JP (1) JP4493333B2 (fr)
KR (1) KR20040014655A (fr)
CA (1) CA2450867A1 (fr)
IL (1) IL159368A0 (fr)
MX (1) MXPA03011813A (fr)
RU (1) RU2004102689A (fr)
WO (1) WO2003004653A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017135A1 (fr) * 2003-08-11 2005-02-24 Codexis, Inc. Polypeptides cetoreductase ameliores et polynucleotides associes
US7125693B2 (en) 2002-08-09 2006-10-24 Codexis, Inc. Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
US7132267B2 (en) 2002-08-09 2006-11-07 Codexis, Inc. Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters
US9862978B2 (en) 2013-02-26 2018-01-09 Aminologics Co. Ltd. Method for preparing (2RS)-amino-(3S)-hydroxy-butyric acid and its derivatives

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043555A1 (fr) * 2004-10-19 2006-04-27 Kaneka Corporation Réductase mutante servant à former un biopolymère
US20090104671A1 (en) * 2005-07-20 2009-04-23 Kaneka Corporation Method for producing optically active 2-(n-substituted aminomethyl)-3-hydroxybutyric acid ester
US8945899B2 (en) 2007-12-20 2015-02-03 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase using NADH
US8273558B2 (en) 2005-10-26 2012-09-25 Butamax(Tm) Advanced Biofuels Llc Fermentive production of four carbon alcohols
US20080293086A1 (en) * 2006-09-18 2008-11-27 Cobalt Technologies, Inc. A Delaware Corporation Real time monitoring of microbial enzymatic pathways
EP2066788B1 (fr) 2006-10-02 2014-07-23 Codexis, Inc. Compositions et procédés permettant de produire des statines pures sur le plan stéréoisomérique et produits intermédiaires synthétiques utilisés dans ces procédés
JP5582576B2 (ja) 2007-04-18 2014-09-03 ビュータマックス・アドバンスド・バイオフューエルズ・エルエルシー 活性の高いケトール酸レダクトイソメラーゼ酵素を用いたイソブタノールの発酵生成
US20090081715A1 (en) * 2007-09-07 2009-03-26 Cobalt Technologies, Inc., A Delaware Corporation Engineered Light-Emitting Reporter Genes
ES2575413T3 (es) 2007-12-20 2016-06-28 Butamax (Tm) Advanced Biofuels Llc Cetol-ácido reductoisomerasa que utiliza NADH
WO2009120806A2 (fr) * 2008-03-25 2009-10-01 Cobalt Technologies, Inc. Expression d’oxydoréductases pour augmenter la productivité volumétrique
CL2009000879A1 (es) 2008-04-09 2010-05-07 Talfryn S A Metodo para fabricar un producto en un biorreactor que comprende cultivar microorganismos que son adaptados o mutagenizados para que exhiban por lo menos un 150% de tolerancia al producto; sistema para fabricar un producto; biorreactor.
EP2446044A4 (fr) 2009-06-26 2013-04-10 Cobalt Technologies Inc Système intégré et procédé de production de bioproduit
JP5908729B2 (ja) 2010-01-20 2016-04-26 株式会社カネカ 安定性が向上したｎａｄｈオキシダーゼ変異体とその利用法
KR20140092759A (ko) 2011-03-24 2014-07-24 부타맥스 어드밴스드 바이오퓨얼스 엘엘씨 숙주 세포 및 아이소부탄올의 제조 방법
WO2013002277A1 (fr) 2011-06-28 2013-01-03 株式会社カネカ Procédé de modification d'une fonction enzymatique et variant enzymatique résultant
NZ701099A (en) 2012-05-11 2017-04-28 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase enzymes and methods of use
CN105102616A (zh) 2012-09-26 2015-11-25 布特马斯先进生物燃料有限责任公司 具有酮醇酸还原异构酶活性的多肽
CN109852592B (zh) * 2019-01-14 2022-05-31 中国科学院成都生物研究所 耐热性提高的羰基还原酶突变体
CN109852593B (zh) * 2019-03-28 2020-10-20 洛阳华荣生物技术有限公司 一种重组酮还原酶及在制备r-3-羟基丁酸及其盐中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2235246T3 (es) * 1997-02-07 2005-07-01 Kaneka Corporation Una reductasa novedosa de carbonilo, gen que codifica la misma y metodo de utilizacion.
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAKANISHI M ET AL: "Involvement of two basic residues (Lys-17 and Arg-39) of mouse lung carbonyl reductase in NADP(H)-binding and fatty acid activation: site-directed mutagenesis and kinetic analyses" JOURNAL OF BIOCHEMISTRY, JAPANESE BIOCHEMICAL SOCIETY, TOKYO, JP, vol. 120, 1996, pages 257-263, XP002127500 ISSN: 0021-924X *
See also references of WO03004653A1 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125693B2 (en) 2002-08-09 2006-10-24 Codexis, Inc. Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
US7132267B2 (en) 2002-08-09 2006-11-07 Codexis, Inc. Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters
US7807423B2 (en) 2002-08-09 2010-10-05 Codexis, Inc. Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
WO2005017135A1 (fr) * 2003-08-11 2005-02-24 Codexis, Inc. Polypeptides cetoreductase ameliores et polynucleotides associes
US7629157B2 (en) 2003-08-11 2009-12-08 Codexis, Inc. Ketoreductase polypeptides and related polynucleotides
US7833767B2 (en) 2003-08-11 2010-11-16 Codexis, Inc. Ketoreductase polypeptides and related polynucleotides
US9862978B2 (en) 2013-02-26 2018-01-09 Aminologics Co. Ltd. Method for preparing (2RS)-amino-(3S)-hydroxy-butyric acid and its derivatives

Also Published As

Publication number Publication date
KR20040014655A (ko) 2004-02-14
EP1416050A4 (fr) 2004-12-22
CA2450867A1 (fr) 2003-01-16
WO2003004653A1 (fr) 2003-01-16
IL159368A0 (en) 2004-06-01
US20040248250A1 (en) 2004-12-09
JPWO2003004653A1 (ja) 2004-10-28
RU2004102689A (ru) 2005-05-10
JP4493333B2 (ja) 2010-06-30
MXPA03011813A (es) 2004-07-01

Similar Documents

Publication Publication Date Title
EP1416050A1 (fr) Methode permettant de modifier un enzyme et
Calzadiaz-Ramirez et al. In vivo selection for formate dehydrogenases with high efficiency and specificity toward NADP+
Woodyer et al. Relaxing the nicotinamide cofactor specificity of phosphite dehydrogenase by rational design
Maier et al. Molecular characterization of the 56-kDa CYP153 from Acinetobacter sp. EB104
JP5908729B2 (ja) 安定性が向上したｎａｄｈオキシダーゼ変異体とその利用法
CN111094557B (zh) 醇脱氢酶突变体及其在双芳基手性醇合成中的应用
JP4012257B2 (ja) 新規カルボニル還元酵素、およびこれをコードする遺伝子、ならびにこれらの利用方法
Balke et al. Switching the regioselectivity of a cyclohexanone monooxygenase toward (+)-trans-dihydrocarvone by rational protein design
Wang et al. Characterization of a stereospecific acetoin (diacetyl) reductase from Rhodococcus erythropolis WZ010 and its application for the synthesis of (2 S, 3 S)-2, 3-butanediol
JP3431146B2 (ja) 改変した酵素によるキラル合成
CN110777125B (zh) 一种杂环类药物中间体的高效制备方法
Yang et al. Efficient asymmetric synthesis of ethyl (S)-4-chloro-3-hydroxybutyrate using alcohol dehydrogenase Sm ADH31 with high tolerance of substrate and product in a monophasic aqueous system
Xu et al. Computational design of highly stable and soluble alcohol dehydrogenase for NADPH regeneration
CN106754775A (zh) 一种羰基还原酶突变体及其基因与应用
Itoh et al. PCR-based amplification and heterologous expression of Pseudomonas alcohol dehydrogenase genes from the soil metagenome for biocatalysis
Wu et al. Efficient synthesis of an antiviral drug intermediate using an enhanced short-chain dehydrogenase in an aqueous-organic solvent system
CN113652407A (zh) 羰基还原酶突变体及其不对称合成双手性化合物的应用
Itoh et al. Efficient synthesis of optically pure alcohols by asymmetric hydrogen-transfer biocatalysis: application of engineered enzymes in a 2-propanol–water medium
US20050026250A1 (en) Phosphite dehydrogenase mutants for nicotinamide cofactor regeneration
Liu et al. Tri‐enzyme fusion of tryptophan halogenase achieves a concise strategy for coenzyme self‐sufficiency and the continuous halogenation of L‐tryptophan
CN113249349B (zh) 突变型醇脱氢酶、重组载体及其制备方法和应用
Ordu et al. Protein engineering applications on industrially important enzymes: Candida methylica FDH as a case study
CN116790550A (zh) 一种烟酰胺核糖激酶突变体及其设计方法和应用
CN114277007A (zh) 一种醇脱氢酶突变体及其应用
WO2013002277A1 (fr) Procédé de modification d'une fonction enzymatique et variant enzymatique résultant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070201